Xin Lang Cai Jing·2025-10-23 04:56Core Insights - Junshi Bioscience experienced a decline of 1.15% in stock price on October 22, with a trading volume of 324 million yuan [1] - The company reported a net financing outflow of 10.19 million yuan on the same day, with a total financing and securities balance of 1.399 billion yuan [1] Financing Summary - On October 22, Junshi Bioscience had a financing buy-in amount of 28.94 million yuan, while the financing balance stood at 1.388 billion yuan, accounting for 4.70% of the circulating market value [1] - The financing balance is above the 90th percentile level over the past year, indicating a high level of financing activity [1] Securities Lending Summary - On October 22, the company repaid 1,033 shares in securities lending and sold 200 shares, with a selling amount of 7,708 yuan based on the closing price [1] - The remaining securities lending volume was 292,600 shares, with a balance of 11.275 million yuan, also exceeding the 90th percentile level over the past year [1] Company Overview - Junshi Bioscience, established on December 27, 2012, focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs [2] - The company's main revenue sources include 90.67% from drug sales, 8.74% from technology licensing, and 0.59% from technical services [2] Financial Performance - For the first half of 2025, Junshi Bioscience reported a revenue of 1.168 billion yuan, representing a year-on-year growth of 48.64% [2] - The net profit attributable to shareholders was -413 million yuan, showing a year-on-year improvement of 36.01% [2] Shareholder Structure - As of June 30, 2025, the number of shareholders increased by 5.88% to 31,200, with an average of 24,543 circulating shares per person, a decrease of 5.56% [2] - Major shareholders include Huaxia SSE STAR 50 ETF and E Fund SSE STAR 50 ETF, with changes in their holdings noted [3]